RPRX
NASDAQRoyalty Pharma plc
News · 26 weeks68+433%
2026-03-012026-08-23
Mix3690d
- Insider20(56%)
- SEC Filings6(17%)
- M&A4(11%)
- Other3(8%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- INSIDEREVP & Chairman, Partnering Hite Christopher sold $5,997,250 worth of Class A Ordinary Shares (100,000 units at $59.97) as part of a pre-agreed trading plan and gifted 16,800 units of Class A Ordinary Shares, decreasing direct ownership by 42% to 23,200 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Royalty Pharma plcSCHEDULE 13D/A - Royalty Pharma plc (0001802768) (Subject)
- INSIDEREVP & CFO Coyne Terrance P. sold $645,551 worth of Class A Ordinary Shares (11,002 units at $58.68) as part of a pre-agreed trading plan (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- SECSEC Form 13F-NT filed by Royalty Pharma plc13F-NT - Royalty Pharma plc (0001802768) (Filer)
- SECSEC Form 144 filed by Royalty Pharma plc144 - Royalty Pharma plc (0001802768) (Subject)
- SECSEC Form 144 filed by Royalty Pharma plc144 - Royalty Pharma plc (0001802768) (Subject)
- PRRoyalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 millionNEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma’s economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder. "We are delighted to expand our relationship with Zealand Pharma through a second collaboration, supporting the company as it continues to advance its innovative pipeline of medicines for obesity and metabolic health," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "This transaction underscores Royalty Pharma’s role as a long-term
- PRZealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertideCompany announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic interests related to rusfertide, including royalty rights on the potential future global net sales of rusfertide.The agreement unlocks value from a non-core royalty entitlement for redeployment to Zealand Pharma’s key strategic priorities. Copenhagen, Denmark, August 12, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that it has entered into a ro
- INSIDERCEO, Chairman of the Board Legorreta Pablo G. was granted 65,216 units of Class A Ordinary Shares, increasing direct ownership by 5% to 1,307,820 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP & CFO Coyne Terrance P. was granted 11,002 units of Class A Ordinary Shares (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP & Chairman, Partnering Hite Christopher was granted 11,002 units of Class A Ordinary Shares (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP, Research & Investments Urist Marshall was granted 8,252 units of Class A Ordinary Shares (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- SECSEC Form 10-Q filed by Royalty Pharma plc10-Q - Royalty Pharma plc (0001802768) (Filer)
- SECRoyalty Pharma plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Royalty Pharma plc (0001802768) (Filer)
- PRRoyalty Pharma reports second quarter 2026 resultsPortfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14%Net cash provided by operating activities of $728 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million to $3,500 million NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. "Royalty Pharma delivered strong second quarter results with Royalty Receipts growth of 14%," said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. "Our transaction pipeline remains exciting and we continued to bolster our de
- PRRoyalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic InitiativesNEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. Greg will lead Royalty Pharma's outreach efforts with academic and non-profit institutions as well as oversee the Royalty Pharma Translational Prize. Greg joins Royalty Pharma after nearly three decades at the intersection of science, medicine and investing, and most recently served as Senior Vice President, Technology Development at Memorial Sloan Kettering Cancer Center. "We are delighted to welcome Greg to Royalty Pharma," said Pablo Legorreta, Chief Executive Officer and Chairman
- PRRoyalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from NeurimmuneNEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront. Cliramitug is a Phase 3 first-in-class TTR-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy (ATTR-CM), a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the heart. Currently approved therapies for ATTR-CM slow disease progression by preventing ATTR accumulation but do not target amyloid already accumulated in the heart. Cliramitug is currently
- PRRoyalty Pharma declares third quarter 2026 dividendNEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026. About Royalty Pharma plcFounded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companie
- PRRoyalty Pharma to announce second quarter 2026 financial results on August 5, 2026NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma plc Founded in 1996, Royalty Phar
- INSIDEREVP, Research & Investments Urist Marshall sold $508,454 worth of Class A Ordinary Shares (9,099 units at $55.88) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP & Chairman, Partnering Hite Christopher sold $7,345,471 worth of Class A Ordinary Shares (130,000 units at $56.50) as part of a pre-agreed trading plan, decreasing direct ownership by 43% to 40,000 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDERDirector Bassler Bonnie L was granted 689 units of Class A Ordinary Shares, increasing direct ownership by 0.88% to 79,181 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP, Research & Investments Urist Marshall sold $502,067 worth of Class A Ordinary Shares (9,098 units at $55.18) as part of a pre-agreed trading plan, decreasing direct ownership by 50% to 9,099 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP & Chairman, Partnering Hite Christopher sold $8,159,277 worth of Class A Ordinary Shares (150,000 units at $54.40) as part of a pre-agreed trading plan (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDERDirector Weatherman Elizabeth H was granted 4,545 units of Class A Ordinary Shares, increasing direct ownership by 53% to 13,103 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
RPRX FAQ
8 questionsWhat does Royalty Pharma plc do?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that...Where does RPRX stock trade?
Royalty Pharma plc (RPRX) is listed on NASDAQ.What sector and industry is RPRX in?
Royalty Pharma plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Royalty Pharma plc go public?
Royalty Pharma plc (RPRX) completed its IPO in 2020.Does RPRX pay a dividend?
RPRX's most recent ex-dividend date was 2026-08-14 with a cash dividend of $0.23 per share. No future ex-date is on file yet.What are analysts saying about RPRX?
Royalty Pharma plc has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $4900.00 price target on 2026-01-30. Recent price targets range from $2800.00 to $4900.00.What companies are similar to RPRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RPRX side-by-side with any of them on Quantisnow.How can I track RPRX on Quantisnow?
Quantisnow aggregates Royalty Pharma plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RPRX to receive live email and push alerts on every new disclosure.